Global Benign Prostatic Hyperplasia (BPH) Medication Market Research Report 2026(Status and Outlook)
Description
Report Overview
BPH is an enlarged prostate. The prostate goes through two main growth cycles during a man’s life. The first occurs early in puberty, when the prostate doubles in size. The second phase of growth starts around age 25 and goes on for most of the rest of a man""s life. BPH most often occurs during this second growth phase.The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
The global Benign Prostatic Hyperplasia (BPH) Medication market size was estimated at USD 3566.0 million in 2025 and is projected to grow at a compound annual growth rate (CAGR) of 3.40% during the forecast period.
This report offers a comprehensive and in-depth analysis of the global Benign Prostatic Hyperplasia (BPH) Medication market, covering all critical facets from a broad macroeconomic overview to detailed micro-level insights. It examines market size, competitive landscape, emerging development trends, niche segments, key drivers and challenges, as well as conducts SWOT and value chain analyses.
The insights provided enable readers to understand the competitive dynamics within the industry and formulate effective strategies to enhance profitability and market positioning. Additionally, the report presents a clear framework for evaluating the current status and future outlook of business organizations operating in this sector.
A significant focus of this report lies in the competitive landscape of the global Benign Prostatic Hyperplasia (BPH) Medication market. It offers detailed profiles of major players, including their market shares, performance metrics, product portfolios, and operational status. This enables stakeholders to identify leading competitors and gain a nuanced understanding of market rivalry and structure.
In summary, this report serves as an essential resource for industry participants, investors, researchers, consultants, and business strategists, as well as anyone planning to enter or expand their presence in the Benign Prostatic Hyperplasia (BPH) Medication market.
Global Benign Prostatic Hyperplasia (BPH) Medication Market: Market Segmentation Analysis
This research report provides a detailed segmentation of the market by region (country), key manufacturers, product type, and application. Market segmentation divides the overall market into distinct subsets based on factors such as product categories, end-user industries, geographic locations, and other relevant criteria.
A clear understanding of these market segments enables decision-makers to tailor their product development, sales, and marketing strategies more effectively to meet the unique needs of each segment. Leveraging market segmentation insights can significantly enhance targeted approaches, optimize resource allocation, and accelerate product innovation cycles by aligning offerings with the specific demands of diverse customer groups.
Key Company
Astellas Pharma
Eli Lilly
GlaxoSmithKline
Sanofi
ADC Therapeutics
Bayer HealthCare
Bristol-Myers Squibb
Valeant Pharmaceuticals
Endo Pharmaceuticals
Foresee Pharmaceuticals
Merck
Novartis
Advaxis
Teva Pharmaceutical Industries
Urologixs
Agennix
ANI Pharmaceuticals
BHR Pharma
Boehringer Ingelheim
Sanpower Group
Eisai
Ferring
IO THERAPEUTICS
LIDDS
Madrigal Pharmaceuticals
Nymox Pharmaceutical
Spectrum Pharmaceuticals
Takeda Pharmaceuticals
Market Segmentation (by Type)
5-Alpha-Reductase Inhibitors
Beta-Blockers
Botanicals and Traditional Chinese Medicine
Market Segmentation (by Application)
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Geographic Segmentation
North America (USA, Canada, Mexico)
Europe (Germany, UK, France, Russia, Italy, Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific)
South America (Brazil, Argentina, Columbia, Rest of South America)
The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA)
Key Benefits of This Market Research:
Industry drivers, restraints, and opportunities covered in the study
Neutral perspective on the market performance
Recent industry trends and developments
Competitive landscape & strategies of key players
Potential & niche segments and regions exhibiting promising growth covered
Historical, current, and projected market size, in terms of value
In-depth analysis of the Benign Prostatic Hyperplasia (BPH) Medication Market
Overview of the regional outlook of the Benign Prostatic Hyperplasia (BPH) Medication Market:
Chapter Outline
Chapter 1 mainly introduces the statistical scope of the report, market division standards, and market research methods.
Chapter 2 is an executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the Benign Prostatic Hyperplasia (BPH) Medication Market and its likely evolution in the short to mid-term, and long term.
Chapter 3 makes a detailed analysis of the market's competitive landscape of the market and provides the market share, capacity, output, price, latest development plan, merger, and acquisition information of the main manufacturers in the market.
Chapter 4 is the analysis of the whole market industrial chain, including the upstream and downstream of the industry, as well as Porter's five forces analysis.
Chapter 5 introduces the latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 6 provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 7 provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 8 provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 9 shares the main producing countries of Benign Prostatic Hyperplasia (BPH) Medication, their output value, profit level, regional supply, production capacity layout, etc. from the supply side.
Chapter 10 introduces the basic situation of the main companies in the market in detail, including product sales revenue, sales volume, price, gross profit margin, market share, product introduction, recent development, etc.
Chapter 11 provides a quantitative analysis of the market size and development potential of each region in the next five years.
Chapter 12 provides a quantitative analysis of the market size and development potential of each market segment in the next five years.
Chapter 13 is the main points and conclusions of the report.
Key Reasons to Buy this Report:
Access to date statistics compiled by our researchers. These provide you with historical and forecast data, which is analyzed to tell you why your market is set to change
This enables you to anticipate market changes to remain ahead of your competitors
You will be able to copy data from the Excel spreadsheet straight into your marketing plans, business presentations, or other strategic documents
The concise analysis, clear graph, and table format will enable you to pinpoint the information you require quickly
Provision of market value data for each segment and sub-segment
Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market
Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region
Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled
Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players
The current as well as the future market outlook of the industry concerning recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions
Includes in-depth analysis of the market from various perspectives through Porter’s five forces analysis
Provides insight into the market through Value Chain
Market dynamics scenario, along with growth opportunities of the market in the years to come
BPH is an enlarged prostate. The prostate goes through two main growth cycles during a man’s life. The first occurs early in puberty, when the prostate doubles in size. The second phase of growth starts around age 25 and goes on for most of the rest of a man""s life. BPH most often occurs during this second growth phase.The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
The global Benign Prostatic Hyperplasia (BPH) Medication market size was estimated at USD 3566.0 million in 2025 and is projected to grow at a compound annual growth rate (CAGR) of 3.40% during the forecast period.
This report offers a comprehensive and in-depth analysis of the global Benign Prostatic Hyperplasia (BPH) Medication market, covering all critical facets from a broad macroeconomic overview to detailed micro-level insights. It examines market size, competitive landscape, emerging development trends, niche segments, key drivers and challenges, as well as conducts SWOT and value chain analyses.
The insights provided enable readers to understand the competitive dynamics within the industry and formulate effective strategies to enhance profitability and market positioning. Additionally, the report presents a clear framework for evaluating the current status and future outlook of business organizations operating in this sector.
A significant focus of this report lies in the competitive landscape of the global Benign Prostatic Hyperplasia (BPH) Medication market. It offers detailed profiles of major players, including their market shares, performance metrics, product portfolios, and operational status. This enables stakeholders to identify leading competitors and gain a nuanced understanding of market rivalry and structure.
In summary, this report serves as an essential resource for industry participants, investors, researchers, consultants, and business strategists, as well as anyone planning to enter or expand their presence in the Benign Prostatic Hyperplasia (BPH) Medication market.
Global Benign Prostatic Hyperplasia (BPH) Medication Market: Market Segmentation Analysis
This research report provides a detailed segmentation of the market by region (country), key manufacturers, product type, and application. Market segmentation divides the overall market into distinct subsets based on factors such as product categories, end-user industries, geographic locations, and other relevant criteria.
A clear understanding of these market segments enables decision-makers to tailor their product development, sales, and marketing strategies more effectively to meet the unique needs of each segment. Leveraging market segmentation insights can significantly enhance targeted approaches, optimize resource allocation, and accelerate product innovation cycles by aligning offerings with the specific demands of diverse customer groups.
Key Company
Astellas Pharma
Eli Lilly
GlaxoSmithKline
Sanofi
ADC Therapeutics
Bayer HealthCare
Bristol-Myers Squibb
Valeant Pharmaceuticals
Endo Pharmaceuticals
Foresee Pharmaceuticals
Merck
Novartis
Advaxis
Teva Pharmaceutical Industries
Urologixs
Agennix
ANI Pharmaceuticals
BHR Pharma
Boehringer Ingelheim
Sanpower Group
Eisai
Ferring
IO THERAPEUTICS
LIDDS
Madrigal Pharmaceuticals
Nymox Pharmaceutical
Spectrum Pharmaceuticals
Takeda Pharmaceuticals
Market Segmentation (by Type)
5-Alpha-Reductase Inhibitors
Beta-Blockers
Botanicals and Traditional Chinese Medicine
Market Segmentation (by Application)
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Geographic Segmentation
North America (USA, Canada, Mexico)
Europe (Germany, UK, France, Russia, Italy, Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific)
South America (Brazil, Argentina, Columbia, Rest of South America)
The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA)
Key Benefits of This Market Research:
Industry drivers, restraints, and opportunities covered in the study
Neutral perspective on the market performance
Recent industry trends and developments
Competitive landscape & strategies of key players
Potential & niche segments and regions exhibiting promising growth covered
Historical, current, and projected market size, in terms of value
In-depth analysis of the Benign Prostatic Hyperplasia (BPH) Medication Market
Overview of the regional outlook of the Benign Prostatic Hyperplasia (BPH) Medication Market:
Chapter Outline
Chapter 1 mainly introduces the statistical scope of the report, market division standards, and market research methods.
Chapter 2 is an executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the Benign Prostatic Hyperplasia (BPH) Medication Market and its likely evolution in the short to mid-term, and long term.
Chapter 3 makes a detailed analysis of the market's competitive landscape of the market and provides the market share, capacity, output, price, latest development plan, merger, and acquisition information of the main manufacturers in the market.
Chapter 4 is the analysis of the whole market industrial chain, including the upstream and downstream of the industry, as well as Porter's five forces analysis.
Chapter 5 introduces the latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 6 provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 7 provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 8 provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 9 shares the main producing countries of Benign Prostatic Hyperplasia (BPH) Medication, their output value, profit level, regional supply, production capacity layout, etc. from the supply side.
Chapter 10 introduces the basic situation of the main companies in the market in detail, including product sales revenue, sales volume, price, gross profit margin, market share, product introduction, recent development, etc.
Chapter 11 provides a quantitative analysis of the market size and development potential of each region in the next five years.
Chapter 12 provides a quantitative analysis of the market size and development potential of each market segment in the next five years.
Chapter 13 is the main points and conclusions of the report.
Key Reasons to Buy this Report:
Access to date statistics compiled by our researchers. These provide you with historical and forecast data, which is analyzed to tell you why your market is set to change
This enables you to anticipate market changes to remain ahead of your competitors
You will be able to copy data from the Excel spreadsheet straight into your marketing plans, business presentations, or other strategic documents
The concise analysis, clear graph, and table format will enable you to pinpoint the information you require quickly
Provision of market value data for each segment and sub-segment
Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market
Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region
Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled
Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players
The current as well as the future market outlook of the industry concerning recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions
Includes in-depth analysis of the market from various perspectives through Porter’s five forces analysis
Provides insight into the market through Value Chain
Market dynamics scenario, along with growth opportunities of the market in the years to come
Table of Contents
200 Pages
- 1 Research Methodology and Statistical Scope
- 1.1 Market Definition and Statistical Scope of Benign Prostatic Hyperplasia (BPH) Medication
- 1.2 Key Market Segments
- 1.2.1 Benign Prostatic Hyperplasia (BPH) Medication Segment by Type
- 1.2.2 Benign Prostatic Hyperplasia (BPH) Medication Segment by Application
- 1.3 Methodology & Sources of Information
- 1.3.1 Research Methodology
- 1.3.2 Research Process
- 1.3.3 Market Breakdown and Data Triangulation
- 1.3.4 Base Year
- 1.3.5 Report Assumptions & Caveats
- 2 Benign Prostatic Hyperplasia (BPH) Medication Market Overview
- 2.1 Global Market Overview
- 2.1.1 Global Benign Prostatic Hyperplasia (BPH) Medication Market Size (M USD) Estimates and Forecasts (2020-2035)
- 2.1.2 Global Benign Prostatic Hyperplasia (BPH) Medication Sales Estimates and Forecasts (2020-2035)
- 2.2 Market Segment Executive Summary
- 2.3 Global Market Size by Region
- 3 Benign Prostatic Hyperplasia (BPH) Medication Market Competitive Landscape
- 3.1 Company Assessment Quadrant
- 3.2 Global Benign Prostatic Hyperplasia (BPH) Medication Product Life Cycle
- 3.3 Global Benign Prostatic Hyperplasia (BPH) Medication Sales by Manufacturers (2020-2025)
- 3.4 Global Benign Prostatic Hyperplasia (BPH) Medication Revenue Market Share by Manufacturers (2020-2025)
- 3.5 Benign Prostatic Hyperplasia (BPH) Medication Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
- 3.6 Global Benign Prostatic Hyperplasia (BPH) Medication Average Price by Manufacturers (2020-2025)
- 3.7 Manufacturers’ Manufacturing Sites, Areas Served, and Product Types
- 3.8 Benign Prostatic Hyperplasia (BPH) Medication Market Competitive Situation and Trends
- 3.8.1 Benign Prostatic Hyperplasia (BPH) Medication Market Concentration Rate
- 3.8.2 Global 5 and 10 Largest Benign Prostatic Hyperplasia (BPH) Medication Players Market Share by Revenue
- 3.8.3 Mergers & Acquisitions, Expansion
- 4 Benign Prostatic Hyperplasia (BPH) Medication Industry Chain Analysis
- 4.1 Benign Prostatic Hyperplasia (BPH) Medication Industry Chain Analysis
- 4.2 Market Overview of Key Raw Materials
- 4.3 Midstream Market Analysis
- 4.4 Downstream Customer Analysis
- 5 The Development and Dynamics of Benign Prostatic Hyperplasia (BPH) Medication Market
- 5.1 Key Development Trends
- 5.2 Driving Factors
- 5.3 Market Challenges
- 5.4 Industry News
- 5.4.1 New Product Developments
- 5.4.2 Mergers & Acquisitions
- 5.4.3 Expansions
- 5.4.4 Collaboration/Supply Contracts
- 5.5 PEST Analysis
- 5.5.1 Industry Policies Analysis
- 5.5.2 Economic Environment Analysis
- 5.5.3 Social Environment Analysis
- 5.5.4 Technological Environment Analysis
- 5.6 Global Benign Prostatic Hyperplasia (BPH) Medication Market Porter's Five Forces Analysis
- 5.6.1 Global Trade Frictions
- 5.6.2 U.S. Tariff Policy – April 2025
- 5.6.3 Global Trade Frictions and Their Impacts to Benign Prostatic Hyperplasia (BPH) Medication Market
- 5.7 ESG Ratings of Leading Companies
- 6 Benign Prostatic Hyperplasia (BPH) Medication Market Segmentation by Type
- 6.1 Evaluation Matrix of Segment Market Development Potential (Type)
- 6.2 Global Benign Prostatic Hyperplasia (BPH) Medication Sales Market Share by Type (2020-2025)
- 6.3 Global Benign Prostatic Hyperplasia (BPH) Medication Market Size by Type (2020-2025)
- 6.4 Global Benign Prostatic Hyperplasia (BPH) Medication Price by Type (2020-2025)
- 7 Benign Prostatic Hyperplasia (BPH) Medication Market Segmentation by Application
- 7.1 Evaluation Matrix of Segment Market Development Potential (Application)
- 7.2 Global Benign Prostatic Hyperplasia (BPH) Medication Market Sales by Application (2020-2025)
- 7.3 Global Benign Prostatic Hyperplasia (BPH) Medication Market Size (M USD) by Application (2020-2025)
- 7.4 Global Benign Prostatic Hyperplasia (BPH) Medication Sales Growth Rate by Application (2020-2025)
- 8 Benign Prostatic Hyperplasia (BPH) Medication Market Sales by Region
- 8.1 Global Benign Prostatic Hyperplasia (BPH) Medication Sales by Region
- 8.1.1 Global Benign Prostatic Hyperplasia (BPH) Medication Sales by Region
- 8.1.2 Global Benign Prostatic Hyperplasia (BPH) Medication Sales Market Share by Region
- 8.2 Global Benign Prostatic Hyperplasia (BPH) Medication Market Size by Region
- 8.2.1 Global Benign Prostatic Hyperplasia (BPH) Medication Market Size by Region
- 8.2.2 Global Benign Prostatic Hyperplasia (BPH) Medication Market Size by Region
- 8.3 North America
- 8.3.1 North America Benign Prostatic Hyperplasia (BPH) Medication Sales by Country
- 8.3.2 North America Benign Prostatic Hyperplasia (BPH) Medication Market Size by Country
- 8.3.3 U.S. Market Overview
- 8.3.4 Canada Market Overview
- 8.3.5 Mexico Market Overview
- 8.4 Europe
- 8.4.1 Europe Benign Prostatic Hyperplasia (BPH) Medication Sales by Country
- 8.4.2 Europe Benign Prostatic Hyperplasia (BPH) Medication Market Size by Country
- 8.4.3 Germany Market Overview
- 8.4.4 France Market Overview
- 8.4.5 U.K. Market Overview
- 8.4.6 Italy Market Overview
- 8.4.7 Spain Market Overview
- 8.5 Asia Pacific
- 8.5.1 Asia Pacific Benign Prostatic Hyperplasia (BPH) Medication Sales by Region
- 8.5.2 Asia Pacific Benign Prostatic Hyperplasia (BPH) Medication Market Size by Region
- 8.5.3 China Market Overview
- 8.5.4 Japan Market Overview
- 8.5.5 South Korea Market Overview
- 8.5.6 India Market Overview
- 8.5.7 Southeast Asia Market Overview
- 8.6 South America
- 8.6.1 South America Benign Prostatic Hyperplasia (BPH) Medication Sales by Country
- 8.6.2 South America Benign Prostatic Hyperplasia (BPH) Medication Market Size by Country
- 8.6.3 Brazil Market Overview
- 8.6.4 Argentina Market Overview
- 8.6.5 Columbia Market Overview
- 8.7 Middle East and Africa
- 8.7.1 Middle East and Africa Benign Prostatic Hyperplasia (BPH) Medication Sales by Region
- 8.7.2 Middle East and Africa Benign Prostatic Hyperplasia (BPH) Medication Market Size by Region
- 8.7.3 Saudi Arabia Market Overview
- 8.7.4 UAE Market Overview
- 8.7.5 Egypt Market Overview
- 8.7.6 Nigeria Market Overview
- 8.7.7 South Africa Market Overview
- 9 Benign Prostatic Hyperplasia (BPH) Medication Market Production by Region
- 9.1 Global Production of Benign Prostatic Hyperplasia (BPH) Medication by Region(2020-2025)
- 9.2 Global Benign Prostatic Hyperplasia (BPH) Medication Revenue Market Share by Region (2020-2025)
- 9.3 Global Benign Prostatic Hyperplasia (BPH) Medication Production, Revenue, Price and Gross Margin (2020-2025)
- 9.4 North America Benign Prostatic Hyperplasia (BPH) Medication Production
- 9.4.1 North America Benign Prostatic Hyperplasia (BPH) Medication Production Growth Rate (2020-2025)
- 9.4.2 North America Benign Prostatic Hyperplasia (BPH) Medication Production, Revenue, Price and Gross Margin (2020-2025)
- 9.5 Europe Benign Prostatic Hyperplasia (BPH) Medication Production
- 9.5.1 Europe Benign Prostatic Hyperplasia (BPH) Medication Production Growth Rate (2020-2025)
- 9.5.2 Europe Benign Prostatic Hyperplasia (BPH) Medication Production, Revenue, Price and Gross Margin (2020-2025)
- 9.6 Japan Benign Prostatic Hyperplasia (BPH) Medication Production (2020-2025)
- 9.6.1 Japan Benign Prostatic Hyperplasia (BPH) Medication Production Growth Rate (2020-2025)
- 9.6.2 Japan Benign Prostatic Hyperplasia (BPH) Medication Production, Revenue, Price and Gross Margin (2020-2025)
- 9.7 China Benign Prostatic Hyperplasia (BPH) Medication Production (2020-2025)
- 9.7.1 China Benign Prostatic Hyperplasia (BPH) Medication Production Growth Rate (2020-2025)
- 9.7.2 China Benign Prostatic Hyperplasia (BPH) Medication Production, Revenue, Price and Gross Margin (2020-2025)
- 10 Key Companies Profile
- 10.1 Astellas Pharma
- 10.1.1 Astellas Pharma Basic Information
- 10.1.2 Astellas Pharma Benign Prostatic Hyperplasia (BPH) Medication Product Overview
- 10.1.3 Astellas Pharma Benign Prostatic Hyperplasia (BPH) Medication Product Market Performance
- 10.1.4 Astellas Pharma Business Overview
- 10.1.5 Astellas Pharma SWOT Analysis
- 10.1.6 Astellas Pharma Recent Developments
- 10.2 Eli Lilly
- 10.2.1 Eli Lilly Basic Information
- 10.2.2 Eli Lilly Benign Prostatic Hyperplasia (BPH) Medication Product Overview
- 10.2.3 Eli Lilly Benign Prostatic Hyperplasia (BPH) Medication Product Market Performance
- 10.2.4 Eli Lilly Business Overview
- 10.2.5 Eli Lilly SWOT Analysis
- 10.2.6 Eli Lilly Recent Developments
- 10.3 GlaxoSmithKline
- 10.3.1 GlaxoSmithKline Basic Information
- 10.3.2 GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Medication Product Overview
- 10.3.3 GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Medication Product Market Performance
- 10.3.4 GlaxoSmithKline Business Overview
- 10.3.5 GlaxoSmithKline SWOT Analysis
- 10.3.6 GlaxoSmithKline Recent Developments
- 10.4 Sanofi
- 10.4.1 Sanofi Basic Information
- 10.4.2 Sanofi Benign Prostatic Hyperplasia (BPH) Medication Product Overview
- 10.4.3 Sanofi Benign Prostatic Hyperplasia (BPH) Medication Product Market Performance
- 10.4.4 Sanofi Business Overview
- 10.4.5 Sanofi Recent Developments
- 10.5 ADC Therapeutics
- 10.5.1 ADC Therapeutics Basic Information
- 10.5.2 ADC Therapeutics Benign Prostatic Hyperplasia (BPH) Medication Product Overview
- 10.5.3 ADC Therapeutics Benign Prostatic Hyperplasia (BPH) Medication Product Market Performance
- 10.5.4 ADC Therapeutics Business Overview
- 10.5.5 ADC Therapeutics Recent Developments
- 10.6 Bayer HealthCare
- 10.6.1 Bayer HealthCare Basic Information
- 10.6.2 Bayer HealthCare Benign Prostatic Hyperplasia (BPH) Medication Product Overview
- 10.6.3 Bayer HealthCare Benign Prostatic Hyperplasia (BPH) Medication Product Market Performance
- 10.6.4 Bayer HealthCare Business Overview
- 10.6.5 Bayer HealthCare Recent Developments
- 10.7 Bristol-Myers Squibb
- 10.7.1 Bristol-Myers Squibb Basic Information
- 10.7.2 Bristol-Myers Squibb Benign Prostatic Hyperplasia (BPH) Medication Product Overview
- 10.7.3 Bristol-Myers Squibb Benign Prostatic Hyperplasia (BPH) Medication Product Market Performance
- 10.7.4 Bristol-Myers Squibb Business Overview
- 10.7.5 Bristol-Myers Squibb Recent Developments
- 10.8 Valeant Pharmaceuticals
- 10.8.1 Valeant Pharmaceuticals Basic Information
- 10.8.2 Valeant Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Product Overview
- 10.8.3 Valeant Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Product Market Performance
- 10.8.4 Valeant Pharmaceuticals Business Overview
- 10.8.5 Valeant Pharmaceuticals Recent Developments
- 10.9 Endo Pharmaceuticals
- 10.9.1 Endo Pharmaceuticals Basic Information
- 10.9.2 Endo Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Product Overview
- 10.9.3 Endo Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Product Market Performance
- 10.9.4 Endo Pharmaceuticals Business Overview
- 10.9.5 Endo Pharmaceuticals Recent Developments
- 10.10 Foresee Pharmaceuticals
- 10.10.1 Foresee Pharmaceuticals Basic Information
- 10.10.2 Foresee Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Product Overview
- 10.10.3 Foresee Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Product Market Performance
- 10.10.4 Foresee Pharmaceuticals Business Overview
- 10.10.5 Foresee Pharmaceuticals Recent Developments
- 10.11 Merck
- 10.11.1 Merck Basic Information
- 10.11.2 Merck Benign Prostatic Hyperplasia (BPH) Medication Product Overview
- 10.11.3 Merck Benign Prostatic Hyperplasia (BPH) Medication Product Market Performance
- 10.11.4 Merck Business Overview
- 10.11.5 Merck Recent Developments
- 10.12 Novartis
- 10.12.1 Novartis Basic Information
- 10.12.2 Novartis Benign Prostatic Hyperplasia (BPH) Medication Product Overview
- 10.12.3 Novartis Benign Prostatic Hyperplasia (BPH) Medication Product Market Performance
- 10.12.4 Novartis Business Overview
- 10.12.5 Novartis Recent Developments
- 10.13 Advaxis
- 10.13.1 Advaxis Basic Information
- 10.13.2 Advaxis Benign Prostatic Hyperplasia (BPH) Medication Product Overview
- 10.13.3 Advaxis Benign Prostatic Hyperplasia (BPH) Medication Product Market Performance
- 10.13.4 Advaxis Business Overview
- 10.13.5 Advaxis Recent Developments
- 10.14 Teva Pharmaceutical Industries
- 10.14.1 Teva Pharmaceutical Industries Basic Information
- 10.14.2 Teva Pharmaceutical Industries Benign Prostatic Hyperplasia (BPH) Medication Product Overview
- 10.14.3 Teva Pharmaceutical Industries Benign Prostatic Hyperplasia (BPH) Medication Product Market Performance
- 10.14.4 Teva Pharmaceutical Industries Business Overview
- 10.14.5 Teva Pharmaceutical Industries Recent Developments
- 10.15 Urologixs
- 10.15.1 Urologixs Basic Information
- 10.15.2 Urologixs Benign Prostatic Hyperplasia (BPH) Medication Product Overview
- 10.15.3 Urologixs Benign Prostatic Hyperplasia (BPH) Medication Product Market Performance
- 10.15.4 Urologixs Business Overview
- 10.15.5 Urologixs Recent Developments
- 10.16 Agennix
- 10.16.1 Agennix Basic Information
- 10.16.2 Agennix Benign Prostatic Hyperplasia (BPH) Medication Product Overview
- 10.16.3 Agennix Benign Prostatic Hyperplasia (BPH) Medication Product Market Performance
- 10.16.4 Agennix Business Overview
- 10.16.5 Agennix Recent Developments
- 10.17 ANI Pharmaceuticals
- 10.17.1 ANI Pharmaceuticals Basic Information
- 10.17.2 ANI Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Product Overview
- 10.17.3 ANI Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Product Market Performance
- 10.17.4 ANI Pharmaceuticals Business Overview
- 10.17.5 ANI Pharmaceuticals Recent Developments
- 10.18 BHR Pharma
- 10.18.1 BHR Pharma Basic Information
- 10.18.2 BHR Pharma Benign Prostatic Hyperplasia (BPH) Medication Product Overview
- 10.18.3 BHR Pharma Benign Prostatic Hyperplasia (BPH) Medication Product Market Performance
- 10.18.4 BHR Pharma Business Overview
- 10.18.5 BHR Pharma Recent Developments
- 10.19 Boehringer Ingelheim
- 10.19.1 Boehringer Ingelheim Basic Information
- 10.19.2 Boehringer Ingelheim Benign Prostatic Hyperplasia (BPH) Medication Product Overview
- 10.19.3 Boehringer Ingelheim Benign Prostatic Hyperplasia (BPH) Medication Product Market Performance
- 10.19.4 Boehringer Ingelheim Business Overview
- 10.19.5 Boehringer Ingelheim Recent Developments
- 10.20 Sanpower Group
- 10.20.1 Sanpower Group Basic Information
- 10.20.2 Sanpower Group Benign Prostatic Hyperplasia (BPH) Medication Product Overview
- 10.20.3 Sanpower Group Benign Prostatic Hyperplasia (BPH) Medication Product Market Performance
- 10.20.4 Sanpower Group Business Overview
- 10.20.5 Sanpower Group Recent Developments
- 10.21 Eisai
- 10.21.1 Eisai Basic Information
- 10.21.2 Eisai Benign Prostatic Hyperplasia (BPH) Medication Product Overview
- 10.21.3 Eisai Benign Prostatic Hyperplasia (BPH) Medication Product Market Performance
- 10.21.4 Eisai Business Overview
- 10.21.5 Eisai Recent Developments
- 10.22 Ferring
- 10.22.1 Ferring Basic Information
- 10.22.2 Ferring Benign Prostatic Hyperplasia (BPH) Medication Product Overview
- 10.22.3 Ferring Benign Prostatic Hyperplasia (BPH) Medication Product Market Performance
- 10.22.4 Ferring Business Overview
- 10.22.5 Ferring Recent Developments
- 10.23 IO THERAPEUTICS
- 10.23.1 IO THERAPEUTICS Basic Information
- 10.23.2 IO THERAPEUTICS Benign Prostatic Hyperplasia (BPH) Medication Product Overview
- 10.23.3 IO THERAPEUTICS Benign Prostatic Hyperplasia (BPH) Medication Product Market Performance
- 10.23.4 IO THERAPEUTICS Business Overview
- 10.23.5 IO THERAPEUTICS Recent Developments
- 10.24 LIDDS
- 10.24.1 LIDDS Basic Information
- 10.24.2 LIDDS Benign Prostatic Hyperplasia (BPH) Medication Product Overview
- 10.24.3 LIDDS Benign Prostatic Hyperplasia (BPH) Medication Product Market Performance
- 10.24.4 LIDDS Business Overview
- 10.24.5 LIDDS Recent Developments
- 10.25 Madrigal Pharmaceuticals
- 10.25.1 Madrigal Pharmaceuticals Basic Information
- 10.25.2 Madrigal Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Product Overview
- 10.25.3 Madrigal Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Product Market Performance
- 10.25.4 Madrigal Pharmaceuticals Business Overview
- 10.25.5 Madrigal Pharmaceuticals Recent Developments
- 10.26 Nymox Pharmaceutical
- 10.26.1 Nymox Pharmaceutical Basic Information
- 10.26.2 Nymox Pharmaceutical Benign Prostatic Hyperplasia (BPH) Medication Product Overview
- 10.26.3 Nymox Pharmaceutical Benign Prostatic Hyperplasia (BPH) Medication Product Market Performance
- 10.26.4 Nymox Pharmaceutical Business Overview
- 10.26.5 Nymox Pharmaceutical Recent Developments
- 10.27 Spectrum Pharmaceuticals
- 10.27.1 Spectrum Pharmaceuticals Basic Information
- 10.27.2 Spectrum Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Product Overview
- 10.27.3 Spectrum Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Product Market Performance
- 10.27.4 Spectrum Pharmaceuticals Business Overview
- 10.27.5 Spectrum Pharmaceuticals Recent Developments
- 10.28 Takeda Pharmaceuticals
- 10.28.1 Takeda Pharmaceuticals Basic Information
- 10.28.2 Takeda Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Product Overview
- 10.28.3 Takeda Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Product Market Performance
- 10.28.4 Takeda Pharmaceuticals Business Overview
- 10.28.5 Takeda Pharmaceuticals Recent Developments
- 11 Benign Prostatic Hyperplasia (BPH) Medication Market Forecast by Region
- 11.1 Global Benign Prostatic Hyperplasia (BPH) Medication Market Size Forecast
- 11.2 Global Benign Prostatic Hyperplasia (BPH) Medication Market Forecast by Region
- 11.2.1 North America Market Size Forecast by Country
- 11.2.2 Europe Benign Prostatic Hyperplasia (BPH) Medication Market Size Forecast by Country
- 11.2.3 Asia Pacific Benign Prostatic Hyperplasia (BPH) Medication Market Size Forecast by Region
- 11.2.4 South America Benign Prostatic Hyperplasia (BPH) Medication Market Size Forecast by Country
- 11.2.5 Middle East and Africa Forecasted Sales of Benign Prostatic Hyperplasia (BPH) Medication by Country
- 12 Forecast Market by Type and by Application (2026-2035)
- 12.1 Global Benign Prostatic Hyperplasia (BPH) Medication Market Forecast by Type (2026-2035)
- 12.1.1 Global Forecasted Sales of Benign Prostatic Hyperplasia (BPH) Medication by Type (2026-2035)
- 12.1.2 Global Benign Prostatic Hyperplasia (BPH) Medication Market Size Forecast by Type (2026-2035)
- 12.1.3 Global Forecasted Price of Benign Prostatic Hyperplasia (BPH) Medication by Type (2026-2035)
- 12.2 Global Benign Prostatic Hyperplasia (BPH) Medication Market Forecast by Application (2026-2035)
- 12.2.1 Global Benign Prostatic Hyperplasia (BPH) Medication Sales (K MT) Forecast by Application
- 12.2.2 Global Benign Prostatic Hyperplasia (BPH) Medication Market Size (M USD) Forecast by Application (2026-2035)
- 13 Conclusion and Key Findings
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.


